ANDEMBRY (Garadacimab-gxii): A New Dawn in Preventing Hereditary Angioedema Attacks

For those living with the constant uncertainty of hereditary angioedema (HAE), a significant breakthrough has arrived. A new treatment, Andembry® (garadacimab-gxii), was recently approved by the U.S. Food and Drug Administration (FDA) on June 16, 2025, offering a powerful new…